{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-1-study-investigating-the-safety-tolerability-pharmacokinetics-and-preliminary-antitumor-activity-of-hpk1-inhibitor-bgb-26808-alone-or-in-combination-with-anti-pd-1-monoclonal-antibody-tisl\/#breadcrumbitem"}]}